CARTILAGE EXTRACT ( BOVINE ) Chemische Eigenschaften,Einsatz,Produktion Methoden
Weltgesundheitsorganisation (WHO)
A preparation containing calf cartilage and bone marrow extract
was introduced in 1960 for the treatment of degenerative joint disease, and it is
currently registered in several countries. In 1987, a risk-benefit assessment of the
product was commissioned in Germany. This resulted initially in its use being
contraindicated in patients with altered immune responses. Subsequently, the
marketing authorization was suspended in Germany in 1992 when the product was
associated with serious adverse effects.
CARTILAGE EXTRACT ( BOVINE ) Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
